=== Intervention Extract 1 (Treatment) ===
Smjernice
Guidelines
SMJERNICE ZA DIJAGNOZU, LIJEČENJE I PRAĆENJE
BOLESNIKA OBOLJELIH OD RAKA PLUĆA NEMALIH STANICA
GUIDELINES FOR DIAGNOSIS, TREATMENT AND MONITORING
PATIENTS WITH NON-SMALL CELL LUNG CANCER
MIROSLAV SAMARŽIJA, MARKO JAKOPOVIĆ, MARIJO BOBAN, LIDIJA BOŠKOVIĆ,
INGRID BELAC LOVASIĆ, ANTONIO JURETIĆ, DAMIR GUGIĆ, JASNA RADIĆ, SVEN SEIWERTH,
SNJEŽANA TOMIĆ, KSENIJA LUČIN, SANJA PLEŠTINA, MIHOVIL ROGLIĆ, JOŠKO JURIČIĆ,
SILVANA SMOJVER J

=== Intervention Extract 2 (Treatment) ===
e most common male cancer, and one of the most common female cancers. Non-small cell
lung cancers account for 85% of lung cancers. Due to the aggressiveness of the disease and bad prognosis if it is not
diagnosed early, it is important to defi ne and implement standardized approach for diagnostics, treatment and monitoring
of these patients. Treatment modalities include surgery, chemotherapy, radiotherapy, targeted biologic therapy and
immunotherapy according to the stage, specifi c tumour histological subtype and patient condition.
Liječ Vjesn 2017;139:365–371
Smjernice za dijagnozu, liječenje i praće

=== Intervention Extract 3 (Treatment) ===
st common female cancers. Non-small cell
lung cancers account for 85% of lung cancers. Due to the aggressiveness of the disease and bad prognosis if it is not
diagnosed early, it is important to defi ne and implement standardized approach for diagnostics, treatment and monitoring
of these patients. Treatment modalities include surgery, chemotherapy, radiotherapy, targeted biologic therapy and
immunotherapy according to the stage, specifi c tumour histological subtype and patient condition.
Liječ Vjesn 2017;139:365–371
Smjernice za dijagnozu, liječenje i praćenje bolesnika
* Klinika za plućne bolesti Jo

=== Intervention Extract 4 (Treatment) ===
sberg RJ, Rubinstein LV. Randomised trial of lobectomy versus
/adjuvantnog liječenja70 limited resection for T1 N0 non-small cell lung cancer. Lung Cancer
Study Group. Ann Thorac Surg 1995;60: 615–22.
Klinički pregled, KKS, DKS, SE i osnovne biokemijske 4. Scott WJ, Howington J, Feigenberg S i sur. Treatment of non-small cel
pretrage krvi napraviti svaka 3 do 4 mjeseca prve 2 godine, lung cancer stage I and stage II: ACCP evidence-based clinical practice
guidelines (2. izd.). Chest 2007;132:234S–42S.
svakih 6 mjeseci od 3. do 5. godine, potom 1x na godinu. CT
5. Darling GE, Allen MS, Decker PA i sur. R

=== Intervention Extract 5 (Treatment) ===
arinis F, Dediu M i sur. PARAMOUNT: final overall
versus sequential thoracic radiotherapy in combination with mito- survival results of the phase III study of maintenance pemetrexed ver-
mycin, vindesine, and cisplatin in unresectable stage III non-small-cell sus placebo immediately after induction treatment with pemetrexed
lung cancer. J Clin Oncol 1999;17:2692–9. plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J
14. Curran WJ Jr, Paulus R, Langer CJ i sur. Sequential vs. concurrent Clin Oncol 2013;31:2895–902.
chemoradiation for stage III non-small cell lung cancer: randomized 35.

=== Intervention Extract 6 (Treatment) ===
rapy
therapy in locally advanced non-small-cell lung cancer: Groupe Lyon-
for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol
Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo-
Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910–7.
37. Sandler A, Yi J, Dahlberg S i sur. Treatment outcomes by tumor histol-
16. Aupérin A, Le Péchoux C, Rolland E i sur. Meta-analysis of concomi-
ogy in Eastern Cooperative Group Study E4599 of bevacizumab with
tant versus sequential radiochemotherapy in locally advanced non-
paclitaxel/carboplatin for advanced non-small cell lung cancer. J Tho-

=== Intervention Extract 7 (Treatment) ===
Rev 2015;(10):CD010463.
19. Hancock JG, Rosen JE, Antonicelli A i sur. Impact of adjuvant treat- 40. Novello S, Barlesi F, Califano R i sur. Metastatic non-small-cell lung
ment for microscopic residual disease after non-small cell lung cancer cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment
surgery. Ann Thorac Surg 2015;99(2):406–13. and follow-up. Ann Oncol 2016;27:1–27.
20. Douillard JY, Rosell R, De Lena M i sur. Impact of postoperative radia- 41. von Plessen C, Bergman B, Andresen O i sur. Palliative chemotherapy
tion therapy on survival in patients with complete resection and sta

=== Intervention Extract 8 (Treatment) ===
ell lung cancer. J Clin
stage II and IIIA non-small-cell lung cancer: promising long-term Oncol 2007;25:5233–9.
results of the Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell R, Carceremy E, Gervais R i sur. Erlotinib versus standard che-
Oncol 2005:343;3480–7. motherapy as first-line treatment for European patients with advanced
22. Butts CA, Ding K, Seymour L i sur. Randomized phase III trial of EGFR mutation-positive non-small-cell lung cancer (EURTAC): a
vinorelbine plus cisplatin compared with observation in completely multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2

=== Intervention Extract 9 (Treatment) ===
2006;7:719–27. taxel in pulmonary adenocarcinoma. N Engl J Med 2009:3;361(10):
24. Pignon JP, Tribodet H, Scagliotti GV i sur. Lung adjuvant cisplatin
46. Zhou C, Wu JL, Chen G i sur. Erlotinib versus chemotherapy as fi rst-
evaluation: a pooled analysis by the LACE Collaborative Group. J Clin
line treatment for patients with advanced EGFR mutation-positive
Oncol 2008;26:3552–9.
non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre,
25. Strauss GM, Herndon JE 2nd, Maddaus MA i sur. Adjuvant paclitaxel
open-label, randomised, phase 3 study. Lancet Oncol 2011;12(8):
plus carboplatin compared wi

=== Intervention Extract 10 (Treatment) ===
itabine in advanced non-
study of two cisplatin-based regimens and paclitaxel plus gemcitabine small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J
in advanced non-small-cell lung cancer: a phase III trial of the Euro- Clin Oncol 2007;25:1545–52.
pean Organization for Research and Treatment of Cancer Lung Cancer 53. Shaw AT, Kim DW, Nakagawa K i sur. Crizotinib versus chemothe-
Group–EORTC 08975. J Clin Oncol 2003;21:3909–17. rapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:
31. Schiller JH, Harrington D, Belani CP i sur. Comparison of four chemo- 2385–94.
therapy regi

=== Intervention Extract 11 (Treatment) ===
T790M–positive lung cancer. N Engl J Med 2017;
docetaxel versus best suportive care in patients with non small cell lung 376:629–40.
cancer previously treated with platinum-based chemotherapy. J Clin 65. Larkins E, Blumenthal GM, Chen H i sur. FDA Approval: Alectinib for
Oncol 2000;18:2095–103. the treatment of metastatic, ALK-positive non-small cell lung cancer
57. Hanna N, Sheperd FA, Fossella FV i sur. Randomized phase III trial of following crizotinib. Clin Cancer Res 2016;22:5171–6.
pemetrexed versus docetaxel in patients with non-small-cell lung 66. Khozin S, Blumenthal GM, Zhang L i sur. FDA app

=== Intervention Extract 12 (Treatment) ===
i sur. Randomized phase III trial of following crizotinib. Clin Cancer Res 2016;22:5171–6.
pemetrexed versus docetaxel in patients with non-small-cell lung 66. Khozin S, Blumenthal GM, Zhang L i sur. FDA approval: ceritinib for
cancer previously treated with chemotherapy. J Clin Oncol 2004;22: the treatment of metastatic anaplastic lymphoma kinase-positive non-
1589–97. small cell lung cancer. Clin Cancer Res 2015;21(11):2436–9.
58. Nagano T, Kim YH, Goto K i sur. Re-challenge chemotherapy for re- 67. Shepherd FA, Pereira JR, Ciuleanu T i sur. Erlotinib in Previously
lapsed non-small-cell lung cancer.

=== Intervention Extract 13 (Treatment) ===
d 2005;353:
59. Reck M, Kaiser R, Mellemgaard A i sur. Docetaxel plus nintedanib ver- 123–32.
sus docetaxel plus placebo in patients with previously treated non- 68. Tsao MN, Lloyd N, Wong RK i sur. Whole brain radiotherapy for the
small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, ran- treatment of newly diagnosed multiple brain metastases. Cochrane Da-
domised controlled trial. Lancet 2014;15:143–55. tabase Syst Rev 2012;4:CD003869.
60. Borghaei H, Paz-Ares L, Horn L i sur. Nivolumab versus Docetaxel in 69. Temel JS, Greer JA, Muzikansky A i sur. Early palliative care for pa-
Advanced Non

=== Intervention Extract 14 (Treatment) ===
, Reckamp KL, Baas P i sur. Nivolumab versus docetaxel in 70. Vansteenkiste J, Crinò L, Dooms C i sur. 2nd ESMO Consensus Con-
advanced squamous-cell non-small-cell lung cancer. N Engl J Med ference on Lung Cancer: early-stage non-small-cell lung cancer con-
2015;373(2):123–35. sensus on diagnosis, treatment and follow-up. Ann Oncol 2014;25:
62. Herbst RS, Baas P, Kim DW i sur. Pembrolizumab versus docetaxel for 1462–74.
previously treated, PD-L1-positive, advanced non-small-cell lung can- 71. Samaržija M, Gugić D, Radić J i sur. Kliničke upute za dijagnozu,
cer (KEYNOTE-010): a randomised controlled t

=== Intervention Extract 15 (Drug) ===
advanced or metastatic non-small-cell lung cancer. The small cell lung cancer on progression-free and overall survival: a meta-
Swedish Lung Cancer Study Group. J Clin Oncol 2005;23:8380–8. analysis. J Natl Cancer Inst 2013;105:595–605.
27. Delbaldo C, Michiels S, Syz N i sur. Benefi ts of adding a drug to a single 49. Seto T, Kato T, Nishio M i sur. Erlotinib alone or with bevacizumab as
agent or a 2-agent chemotherapy regimen in advanced non-small-cell fi rst-line therapy in patients with advanced non-squamous non-small-
lung cancer. A meta analysis. JAMA 2004;292:470–84. cell lung cancer harbou

=== Intervention Extract 16 (Therapy) ===
i, liječenju i
praćenju ovih bolesnika. Metode liječenja uključuju kirurgiju, kemoterapiju, radioterapiju, ciljanu biološku terapiju i
imunoterapiju ovisno o stadiju bolesti, biološkim obilježjima tumora i općem stanju bolesnika.
Descriptors: C arcinnoma, non-small-cell lung – diagnosis, pathology, therapy; Neoplasm staging; Practice guidelines as
topic; Croatia
Summary. Lung cancer is the most common male cancer, and one of the most common female cancers. Non-small cell
lung cancers account for 85% of lung cancers. Due to the aggressiveness of the disease and bad prognosis if it is not
diagnosed ear

=== Intervention Extract 17 (Therapy) ===
s. Due to the aggressiveness of the disease and bad prognosis if it is not
diagnosed early, it is important to defi ne and implement standardized approach for diagnostics, treatment and monitoring
of these patients. Treatment modalities include surgery, chemotherapy, radiotherapy, targeted biologic therapy and
immunotherapy according to the stage, specifi c tumour histological subtype and patient condition.
Liječ Vjesn 2017;139:365–371
Smjernice za dijagnozu, liječenje i praćenje bolesnika
* Klinika za plućne bolesti Jordanovac, Medicinski fakultet Sveučilišta
oboljelih od raka pluća nemalih stanica

=== Intervention Extract 18 (Therapy) ===
53–63.
379–86. 33. Scagliotti GV, Parikh P, von Pawel J i sur. Phase III study comparing
12. Thomas M, Rübe C, Hoffknecht P i sur. Effect of preoperative chemo- cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemo-
radiation in addition to preoperative chemotherapy: a randomised trial therapy-naive patients with advanced-stage non-small-cell lung cancer.
in stage III non-small cell lung cancer. Lancet Oncol 2008;9:636–48. J Clin Oncol 2008;26:3543–51.
13. Furuse K, Fukuoka M, Kawahara M i sur. Phase III study of concurrent 34. Paz-Ares LG, de Marinis F, Dediu M i sur. PARAMOUNT: final o

=== Intervention Extract 19 (Therapy) ===
Engl J Med 2006;355:
15. Fournel P, Robinet G, Thomas P i sur. Randomized phase III trial of
36. Reck M, von Pawel J, Zatloukal P i sur. Phase III trial of cisplatin plus
sequential chemoradiotherapy compared with concurrent chemoradio-
gemcitabine with either placebo or bevacizumab as fi rst-line therapy
therapy in locally advanced non-small-cell lung cancer: Groupe Lyon-
for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol
Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo-
Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910–7.
37. Sandler A, Yi J, Dahlberg S i sur. Trea

=== Intervention Extract 20 (Therapy) ===
Med 2006;355:
15. Fournel P, Robinet G, Thomas P i sur. Randomized phase III trial of
36. Reck M, von Pawel J, Zatloukal P i sur. Phase III trial of cisplatin plus
sequential chemoradiotherapy compared with concurrent chemoradio-
gemcitabine with either placebo or bevacizumab as fi rst-line therapy
therapy in locally advanced non-small-cell lung cancer: Groupe Lyon-
for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol
Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo-
Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910–7.
37. Sandler A, Yi J, Dahlberg S i sur. Treatment ou

=== Intervention Extract 21 (Therapy) ===
locally advanced non-
paclitaxel/carboplatin for advanced non-small cell lung cancer. J Tho-
small cell lung cancer. J Clin Oncol 2010;28:2181–90.
rac Oncol 2010;5:1416–23.
17. Brunelli A, Charloux A, Bolliger CT i sur. ERS/ESTS clinical guide-
38. Masters GA, Temin S, Christopher G i sur. Systemic Therapy for Stage
lines on fitness for radical therapy in lung cancer patients (surgery and IV Non-Small-Cell Lung Cancer: American Society of Clinical On-
chemo-radiotherapy). Eur Respir J 2009;34:17–41. cology Clinical Practice Guideline Update. J Clin Oncol 2015;33:
18. Rusch VW, Giroux DJ, Kraut MJ i s

=== Intervention Extract 22 (Therapy) ===
r advanced non-small cell lung cancer. J Tho-
small cell lung cancer. J Clin Oncol 2010;28:2181–90.
rac Oncol 2010;5:1416–23.
17. Brunelli A, Charloux A, Bolliger CT i sur. ERS/ESTS clinical guide-
38. Masters GA, Temin S, Christopher G i sur. Systemic Therapy for Stage
lines on fitness for radical therapy in lung cancer patients (surgery and IV Non-Small-Cell Lung Cancer: American Society of Clinical On-
chemo-radiotherapy). Eur Respir J 2009;34:17–41. cology Clinical Practice Guideline Update. J Clin Oncol 2015;33:
18. Rusch VW, Giroux DJ, Kraut MJ i sur. Induction chemoradiation and 3488–515.
surg

=== Intervention Extract 23 (Therapy) ===
cer: ESMO Clinical Practice Guidelines for diagnosis, treatment
surgery. Ann Thorac Surg 2015;99(2):406–13. and follow-up. Ann Oncol 2016;27:1–27.
20. Douillard JY, Rosell R, De Lena M i sur. Impact of postoperative radia- 41. von Plessen C, Bergman B, Andresen O i sur. Palliative chemotherapy
tion therapy on survival in patients with complete resection and stage I, beyond three courses conveys no survival or consistent quality-of-life
II, or IIIA non-small-cell lungcancer treated with adjuvant chemother- benefi ts in advanced non small-cell lung cancer. Br J Cancer 2006;
apy: the adjuvant Navelbine

=== Intervention Extract 24 (Therapy) ===
atients who are nonprogressive after two cycles of
adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected platinum-based chemotherapy in non small-cell lung cancer. J Clin
stage II and IIIA non-small-cell lung cancer: promising long-term Oncol 2007;25:5233–9.
results of the Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell R, Carceremy E, Gervais R i sur. Erlotinib versus standard che-
Oncol 2005:343;3480–7. motherapy as first-line treatment for European patients with advanced
22. Butts CA, Ding K, Seymour L i sur. Randomized phase III trial of EGFR mutation-positive non-sm

=== Intervention Extract 25 (Therapy) ===
nt paclitaxel
open-label, randomised, phase 3 study. Lancet Oncol 2011;12(8):
plus carboplatin compared with observation in stage IB non-small-cell
lung cancer: CALGB 9633 with the Cancer and Leukemia Group B,
47. Gridelli C, De Marinis F, Di Maio M i sur. Gefi tinib as fi rst-line treat-
Radiation Therapy Oncology Group, and North Central Cancer Treat-
ment for patients with advanced non-small-cell lung cancer with acti-
ment Group Study Groups. J Clin Oncol 2008;26(31):5043–51.
vating epidermal growth factor receptor mutation: Review of the evi-
26. Sederholm C, Hillerdal G, Lambert K i sur. Phase

=== Intervention Extract 26 (Therapy) ===
ol 2005;23:8380–8. analysis. J Natl Cancer Inst 2013;105:595–605.
27. Delbaldo C, Michiels S, Syz N i sur. Benefi ts of adding a drug to a single 49. Seto T, Kato T, Nishio M i sur. Erlotinib alone or with bevacizumab as
agent or a 2-agent chemotherapy regimen in advanced non-small-cell fi rst-line therapy in patients with advanced non-squamous non-small-
lung cancer. A meta analysis. JAMA 2004;292:470–84. cell lung cancer harbouring EGFR mutations (JO25567): an open-la-
28. Pujol JL, Barlesi F, Daures JP i sur. Should chemotherapy combina- bel, randomised, multicentre, phase 2 study. Lancet 2014;15:

=== Intervention Extract 27 (Therapy) ===
04;22:777–84.
29. Jiang J, Liang H, Zhou X i sur. A meta-analysis of randomized con- 51. Herbst RS, Giaccone G, Schiller JH i sur. Gefi tinib in combination with
trolled trials comparing carboplatin-based to cisplatin-based chemo- paclitaxel and carboplatin in advanced non-small-cell lung cancer: a
therapy in advanced non-small cell lung cancer. Lung Cancer 2007;57: phase III trial–INTACT 2. J Clin Oncol 2004;22:785–94.
348–58. 52. Gatzemeier U, Pluzanska A, Szczesna A i sur. Phase III study of erlo-
30. Smit EF, van Meerbeeck JP, Lianes P i sur. Three-arm randomized tinib in combination with cisplat

=== Intervention Extract 28 (Therapy) ===
nd Treatment of Cancer Lung Cancer 53. Shaw AT, Kim DW, Nakagawa K i sur. Crizotinib versus chemothe-
Group–EORTC 08975. J Clin Oncol 2003;21:3909–17. rapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:
31. Schiller JH, Harrington D, Belani CP i sur. Comparison of four chemo- 2385–94.
therapy regimens for advanced non-small-cell lung cancer. N Engl J 54. Solomon BJ, Mok T, Kim DW i sur. First-line crizotinib versus chemo-
Med 2002;346:92–8. therapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167–77.
55. Fossella FV, DeVore R, Kerr RN i sur. Randomized phase III trial of 63. Ritt

=== Intervention Extract 29 (Therapy) ===
advanced ALK-positive lung cancer. N Engl J Med 2013;368:
31. Schiller JH, Harrington D, Belani CP i sur. Comparison of four chemo- 2385–94.
therapy regimens for advanced non-small-cell lung cancer. N Engl J 54. Solomon BJ, Mok T, Kim DW i sur. First-line crizotinib versus chemo-
Med 2002;346:92–8. therapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167–77.
55. Fossella FV, DeVore R, Kerr RN i sur. Randomized phase III trial of 63. Rittmeyer A, Barlesi F, Waterkamp D i sur. Atezolizumab versus
docetaxel versus vinorelbine or ifosfamide in patients with advanced docetaxel in patients with prev

